Non-HDL and BP improvements suggest cardiometabolic benefit, but without Phase Angle or DEXA data, we're still measuring outcomes, not quality
Affectionately called 'Lizzie, or Gilly' by diabetic patients and marketed as 'Byetta', exenatide was the first slow-release GLP-1 mimic to reach the market (Schuler, Shearin)
To gain insight into the molecular mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist
[PMID: 40712938] PubMed record related to this compound for laboratory literature review
No organ damage, no hormonal disruption, no carcinogenic signals
injections of 100 nmol kg 1 MK-801 ( n = 8 rats), 100 nmol kg 1 GLP-1 ( n = 8 rats), 100 nmol kg 1 GLP-1MK-801 ( n = 8 rats) or vehicle (isotonic saline, n = 8 rats) for three consecutive days while being offered the choice between chow and kaolin